New Cholesterol Drug Cuts Heart Disease Risk by 50% With Just Two Injections Per Year
Inclisiran, a breakthrough RNA therapy, dramatically lowered dangerous cholesterol levels in real-world patients with minimal side effects.
Summary
A groundbreaking cholesterol medication called inclisiran reduced dangerous LDL cholesterol by over 50% in high-risk heart disease patients, requiring only two injections per year. This real-world study of 240 patients across Italy found the RNA-based therapy lowered cholesterol from an average of 119 mg/dl to 57 mg/dl within three months. Nearly two-thirds of patients reached optimal cholesterol targets, with only 1.3% experiencing mild injection site reactions. The treatment worked especially well in diabetic patients and those taking statins, offering a convenient alternative to daily pills for managing cardiovascular risk.
Detailed Summary
Managing cholesterol is crucial for preventing heart disease and extending healthy lifespan, but many patients struggle with daily medications or experience side effects. A new study reveals promising results for inclisiran, an innovative RNA therapy that requires only two injections annually.
Researchers tracked 240 high-risk cardiovascular patients across 12 Italian medical centers who received inclisiran between 2022-2024. This RNA-based drug works by blocking PCSK9 protein production in the liver, dramatically reducing cholesterol synthesis.
Results were remarkable: average LDL cholesterol plummeted from 119 mg/dl to 57 mg/dl (52% reduction) at three months, with sustained benefits at nine months. Nearly 65% of patients achieved optimal cholesterol targets recommended by European guidelines. Side effects were minimal—only three patients reported mild injection site reactions.
The therapy proved especially effective in diabetic patients (60% cholesterol reduction) and those taking background statin therapy. This suggests inclisiran could be particularly valuable for high-risk individuals who need aggressive cholesterol management but struggle with medication adherence or tolerance.
For longevity-focused individuals, this represents a potential game-changer in cardiovascular risk management. High cholesterol accelerates arterial aging and increases heart attack risk—major factors limiting healthspan. A twice-yearly injection offering sustained cholesterol control could dramatically simplify prevention protocols while improving outcomes.
However, this was an observational study without a control group, and long-term safety data remains limited. The treatment is also expensive and requires specialized administration. Despite these limitations, inclisiran offers hope for more convenient, effective cholesterol management in our quest for extended healthy lifespan.
Key Findings
- Inclisiran reduced LDL cholesterol by 52% with just two injections per year
- Nearly 65% of high-risk patients reached optimal cholesterol targets within 3 months
- Only 1.3% experienced side effects, all mild injection site reactions
- Diabetic patients saw even greater benefits with 60% cholesterol reduction
- Effects remained sustained at 9 months with 50% cholesterol reduction
Methodology
Observational multicenter registry study of 240 high cardiovascular risk patients from 12 lipid clinics in Italy's Veneto region. Patients were followed for 9 months after starting inclisiran therapy between October 2022 and February 2024.
Study Limitations
This was an observational study without a control group, limiting causal inferences. Long-term safety data beyond 9 months is unavailable, and the study population was limited to Italian patients, potentially affecting generalizability to other populations.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.